Official Title: CALGB-30506: A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non-Small-Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy Primary Endpoint: Overall survival (OS) at 5 years Sponsor: Cancer and Leukemia Group B; National Cancer Institute (NCI)